Microglia become progressively activated and seemingly dysfunctional with age, and genetic studies have linked these cells to the pathogenesis of a growing number of neurodegenerative diseases. Here we report a striking buildup of lipid droplets in microglia with aging in mouse and human brains. These cells, which we call 'lipid-droplet-accumulating microglia' (LDAM), are defective in phagocytosis, produce high levels of reactive oxygen species and secrete proinflammatory cytokines. RNAsequencing analysis of LDAM revealed a transcriptional profile driven by innate inflammation that is distinct from previously reported microglial states. An unbiased CRISPR-Cas9 screen identified genetic modifiers of lipid droplet formation; surprisingly, variants of several of these genes, including progranulin (GRN), are causes of autosomal-dominant forms of human neurodegenerative diseases. We therefore propose that LDAM contribute to age-related and genetic forms of neurodegeneration.
M icroglia are the resident immune cells of the CNS and play a pivotal role in the maintenance of brain homeostasis 1 . In the aging brain and in neurodegeneration, microglia lose their homeostatic molecular signature and show profound functional impairments, such as increased production of proinflammatory cytokines, elevated generation of reactive oxygen species (ROS) and buildup of dysfunctional lysosomal deposits indicative of impaired phagocytosis 2 . Recent single-cell transcriptomic studies have revealed several distinct microglia subpopulations and cellular states in aging and disease, including "disease-associated microglia" (DAM) 3 , a presumably protective phagocytic microglia population, and "neurodegenerative microglia" (MGnD) 4 , a dysfunctional microglia phenotype. Furthermore, proliferative-region-associated microglia arise during development and express genes that are also enriched in DAM 5 .
Over 100 years before these technologically advanced genomic studies, Alois Alzheimer was one of the first to describe a unique microglial subset when he observed "many glial cells show [ing] adipose saccules" in brains of patients with dementia (Alzheimer, 1907) 6 . Although microglia had not been identified as a distinct cell type back then, Alzheimer's description of these cells suggests that they were indeed microglia. Over the next few years, multiple studies confirmed this finding and regarded glial lipid accumulation as characteristic for senile dementia 7 . However, after this initial excitement, lipid deposits in microglia had mostly been ignored for almost a century.
Cellular lipid accumulation became of interest in other myeloid cells in the 1970s when 'foamy macrophages' were discovered to contribute to atherosclerotic lesions 8 . Since then, abnormal lipid accumulation has been recognized as a key aspect of immune dysfunction in myeloid cells. In particular, lipid droplets, which are lipid-storing organelles that contain neutral lipids such as glycerolipids and cholesterol, are increasingly being accepted as structural markers of inflammation 9 . Myeloid cells form lipid droplets in response to inflammation and stress, including the aforementioned macrophages in atherosclerotic lesions, leukocytes in inflammatory arthritis and eosinophils in allergic inflammation. Here, lipid droplets are sites of production and storage for eicosanoids and inflammatory cytokines and are further involved in antigen presentation and pathogen clearance 10 . Importantly, lipid-droplet-rich foam cells in atherosclerosis show hallmarks of senescent cells and they seem to be deleterious at all stages of disease 11 .
Surprisingly, lipid droplets have not been studied functionally in brain myeloid cells in humans or vertebrates, and less than a handful of papers report the histological presence of lipid droplets in human brains 12, 13 . That they may have important functions in disease has recently been suggested in a Drosophila model whereby lipid droplet formation has been reported in glia at the onset of neurodegeneration 14 . Oil-red-O-positive 'lipid-laden' cells, including neurons, astrocytes, ependymal cells and IBA1 + cells, have recently been reported in mice and shown to increase with age 15 . Lipid droplets were also induced in lipopolysaccharide Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain from young and aged mice. Consistent with our previous data, we found that the numbers of CARS + lipid-storing microglia were significantly higher in aged than in young mice (50.76% versus 18.93%) ( Fig. 1h,i) .
Lipid droplets are composed of neutral lipids such as glycerolipids (triacylglycerols (TAGs), diacylglycerols (DAGs) and monoacylglycerols (MAGs)) and cholesteryl esters (CEs), yet their content can vary greatly between cell types. We isolated lipid droplets from whole hippocampi of aged mice and, to more specifically determine the content of microglial lipid droplets, from cells sorted via fluorescently activated cell sorting (FACS) from aged hippocampal microglia (Fig. 1j ). Lipidomics analysis revealed that lipid droplets from the whole hippocampus and from aged microglia show a nearly identical lipid distribution and are mainly composed of glycerolipids (41.3% in the hippocampus, 44 .4% in microglia), while CEs were almost absent (1.1% in the hippocampus, 0.7% in microglia) ( Fig. 1k ).
Lipid-droplet-rich microglia have a unique transcriptome signature that is associated with cellular dysfunctions. To determine the transcriptional phenotype of lipid-droplet-containing microglia in the aged brain, we isolated CD11b + CD45 lo microglia from the hippocampi of 18-month-old mice based on their BODIPY + mean fluorescence intensity and analyzed lipid-droplet-low (BODIPY lo ; LD-low) and lipid-droplet-rich (BODIPY hi ; LD-high) microglia by RNA sequencing (RNA-seq) ( Fig. 2a,b ). Of note, we used an optimized microglia isolation strategy that uses mechanical tissue homogenization instead of enzymatic digestion, which keeps microglia largely in a nonactivated state and therefore prevents unwanted bias toward an activated proinflammatory signature 20 . Unsupervised cluster analysis segregated LD-low from LD-high microglia and revealed prominent differences between their transcriptome, with 692 significantly differentially expressed genes ( Fig. 2c,d) .
A pathway analysis of differentially expressed genes revealed that 'phagosome maturation' and 'production of nitric oxide and ROS' , two key functions of microglia that become dysregulated with age, as the most significant pathways associated with LD-high microglia ( Fig. 2e ). Regulated genes in the phagosome maturation pathway included lysosomal genes (CD63, ATP6V1A, ATP6V1C1, ATP6V1G1 and TUBA1), genes involved in vesicular transport (RAB5B and RAB7), and CD22, a negative regulator of phagocytosis in microglia 21 . Interestingly, most genes linked to nitric oxide and ROS generation (for example, CAT, KL, PPP1CB, JAK and RAP1B) were upregulated in LD-high microglia (Fig. 2c ). In addition, LD-high microglia were enriched in lipid-related genes, including PLIN3 and the ATP citrate synthase ACLY, which is involved in lipogenesis ( Supplementary Table 1 ), and 'fatty acid β-oxidation' was one of the top enriched pathways (Extended Data Fig. 2 ). Intriguingly, annotated functional transcriptomics predicted the proinflammatory endotoxin LPS as the most significant upstream regulator, which suggests that there is a link between innate inflammation and lipid droplets in microglia ( Fig. 2f ). Fig. 1 | Microglia in the aged brain accumulate lipid droplets. a, Electron microscope images of microglia from young (3-month-old) and aged (20 month-old) male mice. b, Hippocampi from aged mice stained for BODIPy + (lipid droplets) and TMEM119 + (microglia). The right-most panels show 3D reconstructions of BODIPy + TMEM119 + microglia. Arrows indicate lipid droplets. c-e, Quantification of BODIPy + lipid droplet numbers (c), percentage of BODIPy + TMEM119 + cells (d) and average BODIPy + lipid droplet size (e) in the hippocampus (dentate gyrus). n = 6 mice per group. f, Representative image of PLIN3 + (lipid droplets) and TMEM119 + microglia in aged mice. g, Confocal images of PLIN2 + (lipid droplets) and IBA1 + (microglia) in the human hippocampus of a 22-year-old individual and a 67-year-old individual. Arrows indicate PLIN2 + IBA1 + cells. h,i, Representative images (h) and quantification (i; P = 0.01) of CARS + signals (2,845 cm −1 ) in TMEM119 + microglia in the hippocampus of young and aged mice. n = 5 mice per group. j,k, Experimental schematic of the lipidomics analysis of lipid droplets isolated from whole hippocampus and from FACS-sorted microglia from 20-month old mice (j), and pie charts (values in percentages; each pie chart represents 100%) showing the composition of lipid droplets (k). n = 4 mice per group. Statistical tests: two-sided Student's t-test. Data represent the mean ± s.d. **P < 0.01, ***P < 0.001. Data in f and g were replicated in at least two independent experiments. Scale bars, 1 μm (a), 20 μm (b,g,h), 10 μm (f). Ly, lysosome; n, nucleus.
Finally, we compared the transcriptional profile of LD-high microglia with that of microglia in aging 22 , amyotrophic lateral sclerosis (ALS) 23 and Alzheimer's disease 24 , and of microglia subpopulations recently identified in development, aging and disease, including DAM 3 , MGnD 4 and other microglia clusters reported in previous studies 5, 25 . We found a moderate overlap between genes 
Fig. 2 | RNA-seq of LD-low and LD-high microglia from aged mice reveals transcriptional changes linked to phagocytosis and ROS production.
a, Flow sorting scheme for the isolation of BODIPy lo (LD-low) and BODIPy hi (LD-high) CD11b + CD45 lo cells from the hippocampi of 18-month-old male mice. n = 3 samples per group. Each sample is a pool of microglia from the hippocampi of three mice. b, Representative images of microglia after brain homogenization and marker staining before (top) and after (bottom) FACS sorting. Scale bars, 5 μm. c, Volcano plot showing differentially expressed genes in LD-high versus LD-low microglia. The dashed line represents the q < 0.05 cutoff (two-sided Student's t-test, Benjamini-Hochberg FDR). Genes involved in phagosome maturation (red) and ROS production (purple) are highlighted. d, Heatmap showing the top 50 differentially expressed genes (q < 0.05, ranked by P value; R DeSeq2 package, pairwise comparisons, Benjamini-Hochberg FDR). e, Top canonical pathways identified by IPA that are differentially regulated between LD-high and LD-low microglia. Analysis was based on the top 200 genes ranked by P value (Fisher's exact test, Benjamini-Hochberg FDR). iCOS, inducible T cell co-stimulator; iCOSL, iCOS ligand. f, IPA upstream regulator analysis of top 200 differentially expressed genes between LD-low and LD-high microglia (Fisher's exact test, Benjamini-Hochberg FDR). g, Overlap between genes changing in microglia in aging and neurodegeneration (aging, Alzheimer's disease (AD), ALS, DAM and MGnD), and genes upregulated (yellow) or downregulated (blue) in LD-high microglia. The percentage overlap denotes the fraction of genes in each gene list that are upregulated or downregulated in LD-high microglia.
differentially expressed in LD-high microglia and the cluster 3 microglia identified from a previous study 25 , a microglia subset mainly detected in embryonic day 14.5 brains with a transcriptional signature linked to inflammation and metabolic pathways (Extended Data Fig. 2c -i). Furthermore, genes downregulated in LD-high microglia partially overlapped with published gene sets of microglia in aging and neurodegeneration ( Fig. 2g ). However, the downregulated genes of LD-high microglia primarily matched with genes that were upregulated in microglia in aging and in DAM (for example, AXL, CD74, CLEC7A and CYBB) (Extended Data Fig. 2 ).
Overall, these data suggest that lipid-droplet-containing aged microglia show transcriptional changes of genes related to key microglia functions such as phagocytosis, ROS production and immune signaling, yet they have a unique transcriptome signature that is distinct from previously described microglia states observed in aging and neurodegeneration. We therefore designate this microglia state as LDAM and use this term henceforth.
The innate TLR4 ligand LPS induces lipid droplet formation in microglia.
LPS is the main upstream regulator of genes differentially expressed between LD-low and LD-high microglia (Fig. 2f ), and immune cells such as macrophages, neutrophils and eosinophils accumulate lipid droplets in response to inflammatory conditions 10 . To determine whether inflammation triggers lipid droplet formation in microglia, we treated the mouse microglia-derived BV2 cell line with LPS and found a fivefold increase in the number of BODIPY + cells and BODIPY mean fluorescence compared with control cells ( Fig. 3a-d ). To confirm the identity of these BODIPY-labeled droplets, we used triacsin C, which is an inhibitor of long-chain acyl-CoA synthetase that inhibits de novo synthesis of glycerolipids and prevents lipid droplet formation 17, 26 . Indeed, treatment with triacsin C abolished the LPS-induced increase in BODIPY + cell number and fluorescence ( Fig. 3a-d ).
To explore whether LPS-induced lipid droplets in BV2 cells resemble those in microglia from aged mice, we compared their lipid composition using mass spectrometry. Interestingly, they had a highly similar overall lipid content and a similar composition of neutral lipids, with low amounts of CEs but high levels of glycerolipids (MAG and TAG). In contrast, lipid droplets from the liver contained high levels of CEs ( Fig. 3e ,f; Extended Data Fig. 3 ). In addition, lipid droplets from BV2 cells and from aged microglia showed a similar chain-length distribution of TAG-associated fatty acids, with peaks at 38:2 and 44:5, while liver lipid droplets had a shift toward longer TAG chain fatty acids, with a peak at 52:2 carbon atoms, which is in agreement with a previous report 27 (Fig. 3g ,h).
To determine whether inflammation could induce lipid droplets in vivo, we treated young mice systemically with LPS at a dose that has previously been shown to induce a proinflammatory phenotype in microglia (1 mg per kg body weight of LPS for 4 days 28 ).
Notably, we observed a significant, twofold increase in lipid-droplet-containing microglia (BODIPY + IBA1 + ) in the hippocampus of LPS-treated mice compared with vehicle-treated control mice ( Fig. 3i,j) . Transcriptionally, these BODIPY hi (LD-high) microglia differed from BODIPY lo (LD-low) microglia by expressing 272 different genes ( Fig. 3k ) linked to metabolism, lipid storage and inflammation (Fig. 3l ), and they had a signature similar to LDAM in aging ( Fig. 3m ).
Together, these findings demonstrate that LPS triggers lipid droplet formation in microglia in vitro and in vivo, and that lipiddroplet-containing microglia in young LPS-treated mice show a transcriptional signature that partially overlaps with LDAM. Furthermore, LPS-induced lipid droplets in BV2 cells are highly similar to lipid droplets in aged microglia, thus making this in vitro assay a useful model to study lipid droplets in LDAM.
LDAM have phagocytosis deficits. Impaired phagocytosis is considered a hallmark of microglia aging 2 . Interestingly, 'phagosome maturation' was the top regulated pathway associated with the transcriptome of LDAM ( Fig. 2e ), which is characterized by an upregulation of endosomal and lysosomal genes ( Fig. 4a ) and an increased immunoreactivity for the lysosome-associated protein CD68 in BODIPY + microglia in the hippocampus of aged mice (Fig. 4b,c ). Furthermore, three-dimensional (3D) reconstruction revealed that CD68-immunopositive vesicles often accumulate closely around lipid droplets ( Fig. 4d ), and electron microscopy confirmed an accumulation of lysosomes in lipid-droplet-containing microglia ( Fig. 4e ).
To determine whether lipid-droplet-containing microglia had altered phagocytic activity, we induced lipid droplets in BV2 cells with LPS and exposed the cells to zymosan particles derivatized with pHrodo, which serves as a fluorescent indicator of cellular uptake to acid compartments and lysosomes. In line with previous reports 29 , LPS increased phagocytosis ( Fig. 4f -i) yet, interestingly, zymosan particles were mainly found in the BODIPY − cell population and to a significantly lesser extent in lipid-droplet-rich BODIPY + cells ( Fig. 4f,g ). Furthermore, triacsin C treatment increased zymosan phagocytosis in LPS-treated cells ( Fig. 4h ,i). Of note, to test lipid droplet formation in BV2 cells and its effects on phagocytosis in a system that mimics the aging environment, we treated BV2 cells with aged plasma, which has been shown to activate microglia and to trigger brain aging 30 . Indeed, aged plasma induced lipid droplet formation, and cells with high numbers of lipid droplets showed significantly less zymosan uptake (Extended Data Fig. 4 ).
Next, to analyze phagocytosis in LDAM, we prepared acute organotypic brain slices from 12-month-old mice and treated them with pHrodo Red Zymosan Particles. Remarkably, the percentage of zymosan + BODIPY + microglia was tenfold lower compared with zymosan + BODIPY − microglia (2.1% versus 24.3%), which indicates that LDAM have severe defects in phagocytosing zymosan ( Fig. 4j,k ). In addition, we assessed the phagocytic activity of LDAM in vivo by injecting myelin debris, a phagocytic substrate that accumulates in the aging brain, into the hippocampus of aged mice ( Fig. 4l ). We labeled the myelin debris with a constitutively fluorescent dye (Alexa Fluor 555, A555) and found that LDAM phagocytosed significantly fewer A555 + myelin particles compared with microglia without lipid droplets ( Fig. 4m ,n). Collectively, these data suggest that lipid-droplet-rich microglia exhibit phagocytosis deficits and that increased lipid storage is associated with impaired phagocytosis.
LDAM produce high levels of ROS and show excessive release of proinflammatory cytokines. Aged microglia are one of the main sources of increased ROS levels in the aging brain 2 , and excessive microglial ROS production might contribute to age-related CNS dysfunctions. 'Production of NO and ROS' was the second most significantly regulated pathway in LDAM ( Fig. 2e) , with over 90% of the differentially expressed genes increased ( Fig. 5a ). Consistent with these transcriptional changes, aged hippocampal microglia showed higher fluorescence after treatment with CellROX, a dye that is nonfluorescent in a reduced state but exhibits bright fluorescence after oxidation by ROS, than young microglia (Fig. 5b,c) . Moreover, the CellROX signal was increased by twofold in LD-high microglia compared with LD-low microglia ( Fig. 5d,e ), which suggests that the elevated ROS levels in aged microglia might be specifically driven by the increased ROS generation of LDAM LPS-treatment-induced elevated ROS generation in BV2 cells, and inhibition of lipid droplets with triacsin C was sufficient to significantly reduce ROS levels ( Fig. 5f ,h). Cells with high CellROX fluorescence were often loaded with lipid droplets (Fig. 5g ). Together, these findings demonstrate that LDAM have elevated concentrations of ROS and suggest that lipid droplets mediate LPS-induced ROS generation.
Another characteristic of aged microglia is the increased production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6 under baseline conditions and excessive cytokine release following immune challenge 2 . To determine the cytokine expression profile of LDAM, we acutely isolated hippocampal LD-low and LD-high microglia from aged mice and measured cytokine concentrations in the supernatant using a multiplex array 8 h after stimulation with LPS or saline (as the control). We found that under baseline conditions (saline treatment), LD-high microglia released increased levels of multiple cytokines, including CCL3, CXCL10 and IL-6, compared with LD-low microglia. In addition, LD-high microglia showed a strongly exaggerated release of multiple cytokines, such as IL-10, CCL3, CCL4, IL-6, CCL5, TNF-α, IL-1β, IL-1α, CXCL1 and CXCL10, after LPS treatment compared with LD-low microglia ( Fig. 5i ,j). These findings suggest that LDAM are in a primed activation state that becomes hyperactivated after stimulation with LPS.
CRISPR-Cas9 screen identifies genes linked to neurodegeneration as genetic regulators of lipid droplet formation.
To investigate the genetic regulators of microglial lipid-droplet formation, we performed pooled clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 screens. Informed by our RNA-seq data of LDAM ( Fig. 2c,e ), we chose to screen with a single guide RNA (sgRNA) library targeting ~2,000 genes involved in the lysosomal pathway and protein degradation and in cellular stress, with ten distinct sgRNAs targeting each gene along with ~1,000 negative control sgRNAs 31 . To probe the role of these genes in lipid droplet formation, we used the microglial BV2 cell line to generate a pooled population of targeted BV2 cells for every gene represented in the sgRNA library. LPS was used to induce lipid droplets in these cells.
To identify sgRNAs that inhibited or promoted the formation of lipid droplets, we developed a photoirradiation selection strategy in which BV2 cells are separated on the basis of their capacity to form lipid droplets. By adding iodine atoms to the lipid droplet marker BODIPY (iodo-BODIPY (iBP)), we transformed this molecule into a photosensitizer that induces cell death in iBP + cells after photoexcitation 32 (Fig. 6a ). To prove the efficacy of this photoablation approach, we used Calcein live-cell imaging and found that irradiation of iBP + BV2 cells selectively killed lipid-droplet-rich cells (Fig. 6b,c) .
After three rounds of selection against lipid-droplet-rich cells, we sequenced the sgRNA composition of the selected lipid-dropletnegative BV2 cells. We found 112 genes that were significant positive or negative regulators of lipid droplet formation (P < 0.05; false discovery rate (FDR) < 5%) ( Fig. 6e ). Unexpectedly, the top hits included various genes that have been previously linked to neurodegeneration, including Slc33a1, Snx17, Vps35 and Grn [33] [34] [35] [36] , which hints at a possible relationship between lipid storage in microglia and neurodegeneration.
We generated individual BV2 cell lines with CRISPR deletions of selected hits that were detected as negative (Slc33a1, Grn and Vps35) or positive (Snx17) regulators of lipid droplet formation in the screen. Indeed, BV2 cells with sgRNAs targeting Grn, Slc33a1 and Vps35 had significantly more lipid droplets than BV2 cells with control sgRNAs, and sgRNAs targeting Snx17 inhibited lipid droplet formation after LPS treatment ( Fig. 6f ,g). We used flow cytometry to measure ROS levels and found significantly increased ROS generation in BV2 cells with sgRNAs targeting Grn and Slc33a1 cells under baseline conditions and in Slc33a1 sgRNA expressing cells after LPS treatment ( Fig. 6h ). Next, we assessed phagocytosis by analyzing pHrodo Red Zymosan Bioparticle uptake and found that cells with sgRNAs targeting Grn and Slc33a1 had significant deficits in zymosan uptake compared with control cells. In cells expressing Vps35 sgRNA, phagocytosis was specifically compromised after LPS treatment, but not under baseline conditions ( Fig. 6i ).
Grn −/− mice contain high numbers of lipid-droplet-rich microglia that have functional impairments and a transcriptional signature similar to LDAM. To confirm the findings from our screen in vivo, we analyzed lipid droplet numbers in microglia in Grn −/− mice. GRN mutations are linked to the development of FTD 35 , and Grn −/− mice are used as a model for FTD and are characterized by microglial changes, neuroinflammation and cognitive deficits 37 . Given the results of our CRISPR-Cas9 knockout screen, we hypothesized that the GRN knockout would promote lipid droplet formation. We used middle-aged (9-10 months) mice, because Grn −/− mice at this age already show behavioral changes and brain impairments 37 , while wild-type mice present only minor signs of neuroinflammation and contain low numbers of LDAM. We found that microglia in the Antigen processing and presentation MHCII H2-Ab1
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Mature phagosome hippocampus of Grn −/− mice contained high numbers of lipid droplets, resulting in a twofold higher percentage of BODIPY + microglia and twice as many lipid droplets per cell in Grn −/− mice compared with wild-type littermates ( Fig. 7a-c) . Moreover, we frequently detected BODIPY + IBA1 + microglia in the thalamus and occasionally in the cortex and corpus callosum in Grn −/− mice (Extended Data Fig. 5 ). Compared with LD-low Grn −/− microglia, LD-high microglia showed decreased uptake of pHrhodo zymosan in an in situ slice culture phagocytosis assay ( Fig. 7d,e ), increased levels of CellROX fluorescence in the ROS assay, and elevated secretion of proinflammatory cytokines after stimulation with LPS ( Fig. 7f,g ). Almost 2,000 genes were differentially expressed between LD-high and LD-low microglia (Fig. 7h ), and these were linked to metabolic processes and cellular responses to stress ( Fig. 7i ), pathways that are also enriched in LDAM ( Fig. 2e ; Extended Data Fig. 2b ). Based on both the differences in gene expression ( Fig. 7j ) and the significance of these changes ( Fig. 7k ), LD-high Grn −/− microglia are highly similar to LDAM.
Finally, we sought to explore the transcriptional commonalities of lipid-droplet-rich microglia in aging mice, in Grn −/− mice and in LPS-treated young mice. We found that although only nine common genes were differentially expressed in all three data sets (one of them was the lipid-droplet-specific gene PLIN3), the directionality of expression changes of LDAM genes was remarkably similar for all groups and almost identical for LDAM and LD-high Grn −/− microglia ( Fig. 7l ,m; Extended Data Fig. 6 ). To identify enriched pathways for genes shared between lipid-droplet-rich microglia, we used the nine genes shared between all datasets and additionally included the top 20 common genes between LDAM and LD-high Grn −/− microglia because of their high transcriptional similarity. Interestingly, significant pathways included 'endosome lumen' , 'ROS production' and 'lysosome' , pathways linked to the dysfunctional phenotype observed in LDAM and in LD-high Grn −/− microglia ( Fig. 7n,o) .
Together, these findings validate the in vivo relevance of our in vitro CRISPR screen and confirm that microglia from Grn −/− mice contain lipid droplets. Remarkably, LD-high microglia from Grn −/− mice and LDAM in aging mice have similar functional and transcriptional phenotypes, which suggests that lipid-droplet-containing Grn −/− microglia share the LDAM state.
Discussion
In this study, we identified a novel microglia state in the aging brain and showed that LDAM are characterized by a unique transcriptional signature, severe functional deficits and a proinflammatory phenotype.
What is the role of LDAM in the aging brain?. During aging, microglia undergo profound transcriptional and functional changes.
They are considered to be in a primed state and show an increased baseline production of proinflammatory cytokines such as TNF-α, IL-1β and IL-6, and become hyperactivated following immune challenge 2 . Furthermore, they are compromised in their phagocytic activity and produce elevated levels of ROS 2, 30 . These microglia changes are suggested to play a vital role in age-related neuroinflammation and in structural and functional impairments in the aging brain. Microglia in the LDAM state, which account for more than 50% of all microglia in the aged hippocampus, but not microglia without lipid droplets, showed typical age-related functional impairments and a primed phenotype, which suggests that LDAM may be the primary detrimental microglia state in the aging brain. This is in line with findings that have shown that lipid-dropletcontaining immune cells in the periphery are detrimental, including foamy macrophages in atherosclerosis 11 or lipid-droplet-rich eosinophils in experimental models of allergy 38 . However, lipid droplets have also been correlated with beneficial functions, such as improved host defense and antigen cross-presentation in myeloid cells 10 . In the brain, a protective role has been reported for lipid droplets in glia in a Drosophila model for neurodegeneration 14 .
Whether lipid-droplet-containing cells are beneficial or detrimental may depend on the cell type, the environmental context and the composition of lipid droplets. Ultimately, pharmacological and genetic ablation experiments will be required to define the role of LDAM in brain aging and disease.
What causes lipid droplet formation in LDAM?. Lipid droplets can form due to various environmental and cellular conditions, including elevated concentrations of extracellular lipids, inflammatory events, increased ROS levels and intracellular metabolic changes 39, 40 . In peripheral immune cells, lipid droplets often form in response to inflammation and stress 10 . Interestingly, we found that LPS treatment, which provokes an acute inflammatory response in the brain, led to lipid droplet formation in hippocampal microglia in young mice in vivo and in the microglia BV2 cell line in vitro. Furthermore, we found lipid-droplet-containing microglia in Grn −/− mice, a model for FTD that is characterized by severe chronic neuroinflammation. Here, lipid-droplet-containing microglia were not restricted to the hippocampus but also frequently found in the thalamus. This is of particular interest because it has been shown that in Grn −/− mice, neuroinflammation is most pronounced in the thalamus 41 . These findings are corroborated by previous reports about lipid droplets in microglia that concordantly observed lipid droplet formation under inflammatory or stress conditions. For example, lipid droplets in microglia have been detected in adult mice after induction of ROS by rotenone 14 , in hippocampal slice culture from postnatal day 6-8 mice after treatment with LPS, and in LPS-treated cells of the microglia-like N9 cell line 17 . Thus, we suggest that inflammation plays a key role in the buildup of lipid droplets in microglia, and it is tempting to speculate that age-related neuroinflammation provokes the formation of LDAM.
Besides inflammation, metabolic changes toward increased fatty acid production have been reported to cause lipid droplet formation in immune cells 10 and in cancer cells 42 microglia in LPS-treated young mice and in Grn −/− mice revealed significant enrichment of pathways related to metabolism, including 'TCA cycle and fatty acid β-oxidation' . Moreover, LDAM showed a significantly higher NAD + /NADH ratio compared with microglia without lipid droplets, which implies that there are metabolic alterations in these cells (Extended Data Fig. 7) . These findings suggest that there is increased lipid synthesis in LDAM, yet it remains to be shown to which extent metabolic changes are involved in microglial lipid-droplet formation in aging.
Cholesterol accumulation has recently been observed in phagocytes in a model of experimental autoimmune encephalomyelitis demyelination in aged mice as a result of excessive uptake of myelin debris 44 . Because demyelination is a characteristic of brain aging, we analyzed the cholesterol content of lipid droplets in LDAM. We did not find ultrastructural evidence for cholesterol crystals, and lipidomics analysis revealed that these lipid droplets contained mainly glycerolipids and only low amounts of CE. Moreover, the lipid composition of lipid droplets from young microglia and from old microglia was almost identical (Extended Data Fig. 2 ). Thus, we suggest that demyelination does not contribute to lipid droplet formation in LDAM.
In a Drosophila model of neurodegeneration 14 , lipid droplets in glia form due to an APOE-dependent transfer of lipids from neurons to glia. Given that transcription of APOE and other lipid transporters was either downregulated or not significantly regulated in LDAM ( Supplementary Table 1 ), it is unlikely that this mechanism leads to lipid droplet formation in aged microglia.
Role of lipid droplets in the LDAM functional phenotype.
Increased ROS generation is a main characteristic of LDAM and was observed in peripheral lipid-droplet-containing immune cells. Reports about whether ROS is a cause or consequence of lipid droplet formation are contradictory 45, 46 . Interestingly, our in vitro results demonstrated that pharmacological inhibition of lipid droplet formation with triacsin C prevented ROS generation in BV2 cells, which supports the idea that triglycerides and lipid droplets have a causal role in the LPS-induced generation of ROS. But it is possible that elevated ROS initially trigger lipid droplet formation, and subsequently lipid droplets induce ROS formation and exacerbate intracellular ROS load.
LDAM showed severe phagocytosis deficits compared with microglia without lipid droplets in the aging brain. This finding is in line with a previous report which observed that at the sites of atherosclerotic lesions, lipid-droplet-rich foamy macrophages show decreased phagocytosis activity compared with macrophages without lipid droplets 47 . Again, defective phagocytosis could be a cause or consequence of lipid droplet accumulation. Our in vitro findings showed that pharmacological inhibition of lipid droplet formation significantly increased phagocytosis in BV2 cells, which suggests that lipid droplets have a detrimental role for phagocytosis. The exact mechanism of how lipid droplets might interfere with phagocytosis remains to be shown. In this context, a study of macrophages has shown that engulfment of cellular debris relies on the availability of free fatty acids, which are released following the degradation of lipid droplets, thus linking effective lysis of lipid droplets with successful phagocytosis 48 . Notably, our RNA-seq analysis revealed that ADRB1 and ADRB2, two key enzymes in the process of lipid degradation, were significantly downregulated in LDAM. This suggests that there is impaired lysis of lipid droplets in LDAM, thus the subsequent lack of free fatty acids might be an underlying reason for impaired phagocytosis in these cells.
In addition to enzymatic lysis, lipid droplets can be degraded by lysosomes, a process termed lipophagy. Intriguingly, we observed that LDAM contained high numbers of lysosomes, and these lysosomes accumulated in close contact to lipid droplets. It is possible that in LDAM, lysosomes are used for lipophagy of lipid droplets rather than for degrading phagocytosed material, resulting in impaired phagocytosis. Finally, there is emerging evidence to indicate that lysosomes become dysfunctional in aged microglia 2 . Hence, there is the possibility that in LDAM, lipid droplets accumulate due to defective degradation processes, and lipid droplet accumulation and impaired phagocytosis could be two co-existing yet independent processes that are the consequence of defective lysosomes.
LDAM in neurodegeneration.
Recently, it has been shown that several subsets of microglia with unique molecular and functional phenotypes exist in the healthy, the aged and the degenerating brain [3] [4] [5] . The LDAM transcriptional signature showed almost no overlap with these signatures, and, surprisingly, typical aging genes 22 
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Kl such as AXL, CLEC7A and CYBB, were regulated in a reciprocal direction in LDAM. Furthermore, TREM2 and APOE, two key genes involved in the progression of neurodegeneration that are upregulated in DAM and MGnD, were not regulated in LDAM. Likewise, LDAM showed only low overlap with the transcriptome of recently identified 'lipid-associated macrophages' from mouse and human adipose tissue, a cell population that controls metabolic homeostasis in a TREM2-dependent manner and is transcriptionally similar to DAM 49 . LDAM and DAM also show different functional phenotypes; while DAM are actively phagocytic populations, LDAM are severely impaired in this function. The specific dynamics of the LDAM state and the possible conversion between different microglia states during aging and disease remain to be investigated.
By using pooled CRISPR-Cas9-targeted screening, we discovered genes for which variants cause autosomal-dominant forms of neurodegeneration (SLC33A1, SNX17, GRN, VPS35, CLN3 and NPC2) as genetic modulators of lipid droplet formation in microglia [33] [34] [35] [36] . Indeed, sgRNAs targeting these genes were able to increase (Slc33a1, Grn and Vps35) and decrease (Snx17) lipid droplet loads in microglial BV2 cells. In addition, sgRNAs targeting Grn and Slc33a1 induced significant defects in phagocytosis and increased ROS production in BV2 cells, hence recapitulating the functional impairments of LDAM. Excitingly, knockout of Grn, which causes FTD in people with lossof-function mutations in this gene 35 , resulted in severe accumulation of lipid droplets in microglia in vivo. These lipid-droplet-rich microglia in Grn −/− mice showed a similar transcriptome signature and the same functional impairments as LDAM. The finding of lipiddroplet-containing microglia in Grn −/− mice is corroborated by a recent study that showed that cultured progranulin-deficient macrophages exhibited increased foam cell formation (that is, lipid droplet accumulation) compared with wild-type macrophages 50 . In addition, a recent study reported that loss of GRN leads to intracellular and intralysosomal accumulation of long polyunsaturated TAGs 51 in the brains of humans and mice. Since TAGs are a major component of lipid droplets in LDAM, it is possible that lipid droplet accumulation in GRN-deficient microglia contributes to elevated TAG levels in brains lacking GRN. It has to be shown to what extent lipid-dropletcontaining microglia contribute to disease pathology in FTD.
Together, we showed that LDAM demonstrate a novel state of microglia with a unique transcriptional signature and functional impairments in the aging brain, and we identified lipid-dropletcontaining microglia in a Grn −/− mouse model of chronic neuroinflammation and in an LPS-induced acutely inflamed brain milieu. Future studies will show whether LDAM are a common characteristic of neuroinflammation and whether they have a role in neurodegenerative diseases. In the future, targeting LDAM might represent an attractive and druggable approach to decrease neuroinflammation and to restore brain homeostasis in aging and neurodegeneration, with the goal of improving cognitive functions.
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Methods Animals. Aged C57BL/6J male wild-type mice (18-20 months old) were obtained from the National Institute on Aging, and young C57BL/6J males (2-4 months of age) were purchased from The Jackson Laboratory. Grn −/− mice (B6.129S4(FVB)-Grntm1.1Far/Mmja) and wild-type littermates were bred and aged in-house, but were originally acquired from The Jackson Laboratory. Mice were housed under a 12-h light-dark cycle in pathogen-free conditions in accordance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health.
All animal procedures were approved by the VA Palo Alto Committee on Animal Research and the institutional administrative panel of laboratory animal care at Stanford University. Male mice were used for all experiments.
LPS injections.
Male wild-type mice (3 months old) were intraperitoneally injected with LPS (from E. coli, Sigma) at a dosage of 1 mg per kg body weight once a day for four consecutive days. Control mice were injected with body-weight corresponding volumes of PBS. After 24 h of the last LPS injection, mice were killed, brains were extracted and brain tissue was processed for immunohistochemistry staining (see "Perfusion and tissue processing" and "Immunohistochemistry and BODIPY staining" below) or for microglia isolation (see "Microglia isolation" below).
Electron microscopy. Three-month-old and 20-month-old male C57BL/6J wildtype mice (n = 3 per group) were anesthetized with 3.8% chloral hydrate (w/v) and transcardially perfused with 0.9% saline followed by 2% paraformaldehyde (PFA)/2.5% glutaraldehyde in 0.1 M phosphate buffer (PB; pH 7.4). Brains were removed and postfixed in the same fixative overnight at 4 °C and then stored in 0.1 M PB. Sagittal 200-µm sections were cut on a Leica VT1000S vibratome (Leica). The sections were incubated in 2% osmium (Electron Microscopy Sciences) for 2 h, rinsed in 0.1 M PB, dehydrated in a graded series of ethanol and embedded in Araldite (Durcupan, Electron Microscopy Sciences). Semi-thin (1.5 µm) and ultrathin (70-80 nm) sections of the dentate gyrus were cut using a Reichert Om-U 3 ultramicrotome (Leica). Ultrathin sections were mounted on Formvar-coated 75-mesh copper grids, contrasted with aqueous solutions of uranyl acetate (0.5%) and lead citrate (3%), and analyzed at 80 kV in a EM 910 transmission electron microscope (Zeiss) equipped with a Troendle sharp:eye 2k CCD camera.
To evaluate the ultrastructure of microglia within the dentate gyrus, ten ultrathin sections were analyzed per mouse. Microglia were identified using a combination of ultrastructural characteristics, including a highly electron-dense cytoplasm and nucleus, an often star-shaped cell morphology, an irregularly shaped nucleus with coarsely clumped chromatin, and a cytoplasm-rich in free ribosomes and vesicles 52 . The cytoplasm and nucleus area were analyzed using the software ImageJ v.1.45s.
Perfusion and tissue processing. Mice were anesthetized using Avertin (tribromoethanol) and transcardially perfused with 0.9% NaCl solution. Brains were extracted, fixed in 4% PFA for 48 h, cryoprotected in 30% sucrose and then sectioned sagitally or coronally (40 μm) using a freezing microtome (Leica). Sections were stored at −20 °C in cryoprotectant solution (ethylene glycol, glycerol, 0.1 M PB (pH 7.4), 1:1:2 by volume) until used for immunohistochemistry and CARS imaging.
Immunohistochemistry and BODIPY staining. Free-floating sections were washed three times in PBS followed by 1 h blocking in PBS with 10% donkey serum. Sections were incubated in PBS with 10% donkey serum and the following primary antibodies for 48 h at 4 °C: rabbit anti-TMEM119 (1:400; Abcam, ab209064); rat anti-CD68 (1:200; Bio-Rad, MCA1957GA); rabbit anti-IBA1 (1:1,000; Wako, 019-19741); and guinea pig anti-PLIN3 (1:200; Progen, G37). After primary antibody incubation, sections were washed three times in PBS and incubated in PBS with 10% donkey serum and the following secondary antibodies for 3 h at room temperature (RT): donkey anti-rabbit Alexa Fluor 555, donkey antirabbit Alexa Fluor 647, donkey anti-rabbit Alexa Fluor 405 (all at 1:500 dilution and from Invitrogen), donkey anti-rat Cy5, donkey anti-guinea pig Alexa Fluor 488 (all at 1:500 dilution and from Jackson Immuno Research). Sections were washed once in PBS and incubated in PBS with BODIPY 493/503 (1:1,000 from a 1 mg ml -1 stock solution in dimethylsulfoxide (DMSO); Thermo Fisher), to stain lipid droplets, and Hoechst 33342 (1:2,000; Thermo Fisher), for nuclear counterstaining, for 15 min at RT. Sections were mounted on microscope slides and embedded with Vectashield (Vector Laboratories, H-1000). Note that for successful lipid-droplet staining, antigen retrieval steps and treatment with detergents must be avoided, and sections should be embedded while still wet.
Quantitative analysis of immunohistological data. For quantification of BODIPY + microglia, CD68 hi microglia, BODIPY + lipid droplet numbers and lipid droplet size, analyses were performed blinded on coded slides. Every tenth section (400-μm intervals) of one hemisphere was selected from each animal and processed for immunohistochemistry. Six randomly selected visual fields per animal were photographed using a confocal scanning laser microscope (LSM 700, Zeiss) with LSM software (ZEN 2011) and used for quantitative analysis.
To analyze the percentage of lipid-droplet-containing microglia, numbers of total TMEM119 + or IBA1 + cells and of TMEM119 + BODIPY + or IBA1 + BODIPY + cells were counted, and the percentage of BODIPY + microglia was calculated. To assess the percentage of CD68 hi cells, BODIPY − IBA1 + and BODIPY + IBA1 + cells with clearly visible CD68-immunoreactive particles were counted and normalized to total BODIPY − IBA1 + and BODIPY + IBA1 + cells.
To assess the numbers of lipid droplets per dentate gyrus area, BODIPY + lipid droplets from six randomly selected visual fields (maximum projection of the z stack across the whole section) were manually counted and normalized to the corresponding dentate gyrus area. To determine the average size of lipid droplets, the BODIPY + signal was analyzed using the 'analyze particles' function of ImageJ v.1.45s (ImageJ website: http://imagej.nih.gov.laneproxy.stanford.edu/ij/) for six randomly selected visual fields (maximum projection of the z stack across the entire section).
3D reconstruction of confocal images. Confocal image stacks (acquired at ×63 magnification) of BODIPY + and CD68 + microglia were converted to 3D images with the surface-rendering feature of Imaris BitPlane software (v.7.6.1).
Human postmortem brain tissue. Human hippocampal tissue sections from autopsy samples of young adult (<35 years, n = 3) and elderly (>60 years, n = 5) humans with a postmortem interval of <24 h were used. Human postmortem tissue was obtained from the collection of the Department of Neuropathology at Stanford University. The use of these specimens for scientific purposes was in accordance with institutional ethical guidelines. All samples used were obtained from individuals without any neurological or psychiatric diagnoses. After tissue extraction, the brain samples were stored in 10% formalin. All tissue samples were cut at 50 μm on a vibratome (Leica VT1000S) and stored in PBS at 4 °C.
Immunohistochemistry of formalin-fixed human brain tissue. Formalin-fixed human tissue sections were washed three times in Tris-buffered saline with 0.05% Tween 20 (TBST) followed by incubation in TBST with 10% donkey serum and the following primary antibodies for 72 h at 4 °C: rabbit anti-IBA1 (1:500; Wako, 019-19741) and guinea pig anti-PLIN2 (1:200; Fitzgerald, 20R-AP002). After primary antibody incubation, sections were washed three times in TBST and incubated in TBST with 10% donkey serum and the following secondary antibodies for 3 h at RT: donkey anti-rabbit Alexa Fluor 488, donkey anti-guinea pig Alexa Fluor 555 (all at 1:500 dilution and from Invitrogen). Sections were mounted with Vectashield (Vector Laboratories, H-1000).
CARS imaging. PFA-fixed 40-μm-thick brain sections from 3-month-old and 20-month-old male mice (n = 5 mice per group, 4 sections per animal) were stained with rabbit anti-TMEM119 (1:400; Abcam, ab209064) and donkey antirabbit Alexa Fluor 647 (Jackson Immuno Research) (see the protocol in the section "Immunohistochemistry and BODIPY staining" above). Microscopy was performed using a Leica SP5 confocal microscope with spectral detection (Leica Microsystems) and a Leica HCX PL APO CS ×63 numerical aperture 1.4 oil-immersion objective. Alexa Fluor 647 was excited at 633 nm and emission detected between 650 nm and 700 nm using a hybrid detector. Transmission images were simultaneously acquired. Label-free CARS microscopy was performed using a commercial setup consisting of an optical parametric oscillator pumped by a picosecond laser source (picoEmerald; APE) integrated into the Leica SP5 microscope. The CARS signal was detected using a 650/210 bandpass emission filter and a non-descanned detector in epi-mode. To detect neutral lipids, the laser was tuned to 2,845 cm −1 , thus enabling imaging of CH 2 symmetric stretching vibrations. CARS and fluorescence/transmission images were sequentially acquired. For quantification of the CARS signal in microglia, 20 randomly selected microglia in the dentate gyrus per animal were imaged. The percentage of TMEM119 + microglia with CARS + vesicles from the total TMEM119 + microglia was calculated.
Lipidomics. Five-month-old and 20-month-old male wild-type mice (n = 4 mice per group) were perfused, and the hippocampus and the liver were extracted. Alternatively, hippocampal microglia were FACS-sorted from 20-month-old mice (see the section "Microglia isolation" below). BV2 cells were treated for 18 h with 5 μg ml -1 LPS (from E. coli, Sigma) in DMEM + 5% fetal bovine serum (FBS) to induce lipid droplet formation. Lipid droplets from liver, whole hippocampus, isolated microglia and LPS-treated BV2 cells were isolated using a lipid droplet isolation kit from Cell Biolabs according to the manufacturer's instructions.
Lipid droplets were stored at −70 °C until sample preparation and extracted according to a previously described protocol, but with modifications 53 . Before extraction, 10 µl of a synthetic lipid standard mastermix (including 15 deuterated lipids) was added to 90 µl of extraction buffer containing lipid droplets.
Extracted lipids were analyzed by flow injection analysis shotgun lipidomics using an ekspert MicroLC 200 system (Eskigen) connected to a TripleTOF 4600 System (AB SCIEX). Each sample was injected twice: one for measurement in the positive ionization mode and one for the negative ionization mode. Instrumental controlling and data acquisition were achieved using the software Analyst TF (v.1.7, AB SCIEX).
Data were processed using Lipid View (v.1.3 beta, AB SCIEX). Lipid identification was based on precursor ion and neutral loss scans specific for Articles NATuRE NEuRoSCIENCE proposed lipid species. Internal standard correction for each lipid was carried out by normalization against the appropriate synthetic isotopically labeled lipid standard.
Microglia isolation. Primary microglia were isolated as previously described 20 . Mice were perfused with medium A (HBSS, 15 mM HEPES, 0.05% glucose and 1:500 DNase I), and hippocampi were dissected. Hippocampi were chopped and homogenized using a Dounce homogenizer in 2 ml of cold medium A, filtered through a 100-μm cell strainer, rinsed with 5 ml medium A and centrifuged at 340 × g for 5 min. For myelin removal, the precipitate was resuspended in 30% standard isotonic Percoll (30% Percoll in PBS, diluted with medium A) and centrifuged at 900 × g for 20 min. Precipitated cells were washed with HBSS and resuspended in FACS buffer (PBS, 1% BSA and 2 mM EDTA). The samples were stained with 1:300 CD11b-PE and 1:300 CD45-APC for 30 min at RT, centrifuged at 400 × g for 5 min, resuspended in PBS with BODIPY 493/503 (1:2,000 from a 1 mg ml -1 stock solution in DMSO; Thermo Fisher) and incubated for 10 min at 37 °C. Cells were washed two times with FACS buffer and resuspended in FACS buffer with DNase I and 5 μl ml -1 RNAse inhibitor (Clontech). Dead cells were excluded by staining with Sytox Blue dead cell stain (1:10,000; Invitrogen). Cells were isolated using an ARIA 3.1 (BD Biosciences) with FACSDiva (BD Biosciences), sorted into RLT lysis buffer (Qiagen) with 1% 2-mercaptoethanol and frozen at −80 °C.
RNA isolation and library preparation.
Frozen cells were thawed to RT and total RNA was isolated from the cell pellets using a RNeasy Plus Micro kit (Qiagen, 74034). RNA quantities and RNA quality were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies). All samples that passed a quality control threshold (RNA integrity number of ≥9.0) proceeded to library preparations and RNA-seq. Total mRNA was transcribed into full-length complementary DNA using a SMART-Seq v4 Ultra Low Input RNA kit (Clontech) according to the manufacturer's instructions. Samples were validated using the Agilent 2100 Bioanalyzer and an Agilent High Sensitivity DNA kit. Full-length cDNA (150 pg) was processed using a Nextera XT DNA library preparation kit (Illumina) according to the manufacturer's protocol. Library quality was verified using the Agilent 2100 Bioanalyzer and the Agilent High Sensitivity DNA kit. Sequencing of microglia isolated from aged wild-type mice was carried out using an Illumina HiSeq 2000/2500, paired end, 2× 100 bp depth sequencer, and microglia from 10-month-old Grn −/− mice and from 3-month-old LPS-treated mice were sequenced using an Illumina Novogene 6000, paired end, 2× 100 bp depth sequencer. The quality of fastq files was assessed using FASTQC (v.0.11.4). Reads were mapped to the mouse mm9 reference genome using STAR (v.2.5.1b). Raw read counts were generated with STAR using the GeneCounts function.
RNA-seq differential expression. Differential expression in RNA-seq was analyzed using the package R DESeq2 (ref. 54 ). Read counts were used as input and normalized using built-in algorithms in DESeq2. Pairwise comparisons among the two groups (BODIPY lo and BODIPY hi microglia) were done on all genes, and 12,129 genes with calculable fold changes and FDRs were used for further analysis. The FDR was estimated using the Benjamini and Hochberg approach 55 . R was used for RNA-seq data visualization and ingenuity pathway analysis (IPA), and Enrichr were used to analyze pathways and upstream regulators.
For comparisons of transcriptome changes in LDAM with published datasets ( Fig. 2g ; Extended Data Fig. 3 ), we selected the following published RNA-seq datasets of microglia in aging and neurodegeneration (modified after Bohlen et al., 2017) 56 : 24-month versus 4-month-old wild-type mice for aging (Holtman et al., 2015) 22 ; APP + versus APPfor Alzheimer's disease (Wang et al., 2015) 24 ; SOD G93A endstage versus nontransgenic day 130 for ALS (Chiu et al., 2013) 23 25 . For gene set comparisons, we generated lists for the published datasets by using a fold change cutoff (modified after Bohlen et al., 2017) 56 and compared these lists with the top 100 upregulated and downregulated genes in LDAM.
BV2 cell culture. Cells from the murine microglial BV2 cell line were originally obtained from Banca Biologica e Cell Factory, IRCCS Azienda Ospedaliera Universitaria San Martino, Genua, Italy. Cells were maintained in DMEM (Life Technologies) supplemented with 10% FBS and antibiotics (penicillin 100 U ml −1 , streptomycin 100 U ml −1 (pen/strep), HVD Life Sciences) under standard culture conditions (95% relative humidity with 5% CO 2 at 37 °C). Adherent cells were split using 1× TrypLE (Gibco).
LPS and triacsin C treatment.
To induce lipid droplet formation, subconfluent BV2 cells were treated for 18 h with 5 μg ml -1 LPS (from E. coli, Sigma) in DMEM + 5% FBS. Controls received vehicle solution (PBS) only. To inhibit lipid droplet formation, BV2 cells were pretreated with 1 μM triacsin C (Cayman Chemical) or vehicle (saline) in DMEM + 5% FBS. After 30 min of adding triacsin C, LPS or LPS-vehicle solution was added, and cells were co-treated with triacsin C and LPS for 18 h.
Plasma collection. Blood from young (2-month-old) and aged (18-month-old) wild-type mice was collected (with EDTA as the anticoagulant) via intracardial bleeding at the time of death. EDTA plasma was obtained from freshly collected blood by centrifugation (1,000 × g for 10 min at 4 °C), aliquoted and stored at −80 °C until use. For BV2 experiments, thawed plasma was dialyzed in PBS to remove EDTA, and then delipidized using a lipid removal adsorbent (Sigma). Briefly, plasma was mixed with lipid removal adsorbant (40 mg ml -1 ) for 60 min at RT, centrifuged at 2,200 × g for 2 min, and the supernatant was collected. Dialyzed and delipidized plasma was diluted to a working concentration (5%) in DMEM + 5% FBS and incubated for 20 min at RT to allow to clot. The solution was filtered through a polyethersulfone 0.22-µm filter unit and used for cell culture assays.
Plasma treatment. BV2 cells were treated for 18 h with 5% plasma (for preparation see the section "Plasma collection") in DMEM + 5% FBS. Controls received vehicle solution (PBS) only.
BODIPY in vitro staining. BV2 cells were seeded at 5 × 10 4 cells on poly-l-lysinecoated glass coverslips in DMEM + 5% FBS. Following specific treatments, cells were fixed in 4% PFA for 30 min, washed three times in PBS and incubated in PBS with BODIPY 493/503 (1:1,000 from a 1 mg ml -1 stock solution in DMSO; Thermo Fisher) and Hoechst 33342 (1:2,000; Thermo Fisher) for 10 min at RT. Sections were washed twice in PBS and mounted on microscope slides with Vectashield (Vector Laboratories, H-1000). Four randomly selected visual fields per coverslip were photographed (×40 magnification) using a confocal scanning laser microscope (LSM 700, Zeiss) with LSM software (ZEN 2011). To analyze the percentage of lipid-droplet-containing BV2 cells, the numbers of total Hoechst + cells and of Hoechst + cells with BODIPY + lipid droplets were counted, and the percentage of BODIPY + BV2 cells was calculated.
In vitro phagocytosis assay. For in vitro phagocytosis assays, BV2 cells were split into 96-well plates at 1,000 cells per well in DMEM + 5% FBS and treated with LPS, triacsin C and vehicle solutions, or with 5% plasma and vehicle, for 18 h. Following specific treatments, 5 ng of pHRodo Red Zymosan Bioparticles (Thermo Fisher Scientific, P35364) in 100 μl of DMEM + 5% FBS was added per well. Four phasecontrast and red fluorescent images per well were acquired every 2 h for 16 h using an Incucyte S3 live cell analysis system (Essen Bioscience). For each time point, phagocytosis was calculated by normalizing the red fluorescent area to the phase confluence.
Organotypic brain slices and in situ phagocytosis assay. Twelve-month-old male wild-type mice (n = 3 mice) and 9-month-old male Grn −/− mice were decapitated, and dissected brains were immediately put in precooled culture medium with serum (65% MEM (Sigma), 10% horse serum, 25% HBSS, 6.5 mg ml -1 glucose, 2 mM glutamine and 1% pen/strep).
The entire procedure was done on ice with precooled solutions until culturing. Coronal sections were prepared using a vibratome (Leica VT1000S) at 250-μm thickness and then transferred to insert wells (Millicell Cell Culture Insert, 30 mm, Millipore) on a 6-well plate with medium. Sections were incubated for 1 h in the incubator (37 °C, 5% CO 2 ). pHrodo Red Zymosan Bioparticles (Thermo Fisher Scientific) were opsonized (three washes in PBS, followed by incubation in 50% FBS in PBS for 45 min at 37 °C and three washes in PBS) and added at 0.5 mg ml -1 to cover the entire section (about 150 μl each). The plate was incubated for 4 h (37 °C, 5% CO 2 ). After washes with PBS, sections were fixed with 4% PFA for 30 min at RT. Immunohistochemistry for IBA1 and BODIPY staining was performed as described above.
To measure phagocytosis in BODIPY − and BODIPY + microglia, four randomly selected visual fields per section (three sections per mouse) were photographed using a confocal scanning laser microscope (LSM 700, Zeiss) with LSM software (ZEN 2011). The numbers of BODIPY − IBA1 + and BODIPY + IBA1 + cells were quantified, and the percentage of zymosan-containing cells was calculated.
In vivo phagocytosis assay. Alexa-Fluor-555-labeled myelin (25 mg ml -1 in PBS) was injected into the hippocampus of 20-month-old male mice using a stereotaxic apparatus (Kopf Instruments). Mice were anesthetized using isofluorane, their skulls were exposed and a hole was drilled at the injection site using aseptic techniques. One microliter of the myelin solution was injected at ±0.7-mm lateral, −1.7-mm anteroposterior and −2.04-mm dorsoventral relative to the intersection of the coronal and sagittal suture (bregma) at a rate of 200 nl min -1 . The needle was left in place for an additional 3 min to allow for diffusion, then slowly withdrawn. Mice received post-surgical buprenorphine and baytril for pain and infection prevention, respectively. After 48 h, mice were anesthetized and transcardially perfused with 4% PFA. The entire injection site was sectioned (coronal, 40-μm thick) and stained for IBA1 and BODIPY as described above. Five to eight sections were quantified to assess myelin uptake of BODIPY + IBA1 + cells and BODIPY − IBA1 + cells.
ROS assay.
To assess ROS generation in primary microglia, cell homogenates from 3-month-old and 20-month-old male wild-type mice and from 9-month-old male
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Grn −/− mice were prepared, and antibody staining was performed as described above (see the section "Microglia isolation"). Cell homogenates were incubated in FACS buffer with CellROX Deep Red (1:500; Invitrogen) for 30 min at 37 °C, washed twice in FACS buffer, and CellROX Deep Red Intensity was analyzed on an ARIA 3.1 instrument (BD Biosciences).
To measure ROS in BV2 cells, cells were split into 24-well plates at 5 × 10 4 cells per well in DMEM + 5% FBS and treated with LPS, triacsin C and vehicle solutions for 18 h. Next, cells were incubated in DMEM + 5%FBS with CellROX Orange (1:500; Invitrogen) for 30 min at 37 °C, washed twice in PBS, and CellROX Orange Intensity was examined by fluorescence microscopy (Keyence). Following microscopy analysis, cells were detached using TripLE, transferred to FACS tubes, and CellROX Orange intensity was analyzed on a BD AccuriC6 flow cytometer. iBP irradiation assay. BV2 cells were treated for 18 h with 5 μg ml -1 LPS in DMEM with 5% FBS to induce lipid droplet formation. Controls received vehicle solution (PBS) only. Cells were washed twice in PBS and incubated in 3.8 μM iBP solution (see Fig. 6a ; iBP was provided by C. Bertozzi, Chemistry Department, Stanford University) in PBS for 30 min in the incubator (5% CO 2 , 37 °C). Cells were washed twice in PBS and then irradiated under visible light (green light-emitting diode; 9 W, 150 mA, 2,000 lux) for 3 h at RT. Nonirradiated cells were kept at RT for 3 h without irradiation.
Calcein AM live cell staining. To assess cell viability after photoirradiation, irradiated and nonirradiated BV2 cells were stained with 1 μM Calcein AM (Invitrogen) in PBS for 15 min at 37 °C. Cells were then examined by fluorescence microscopy (Keyence), and the percentage of green, Calcein + BV2 cells (live cells) of total methyl-di-iodo BODIPY + cells (red, lipid-droplet-containing cells) was calculated.
CRISPR-Cas9 screen. The 10-sgRNA-per-gene CRISPR-Cas9 deletion library was synthesized, cloned and infected into Cas9-expressing BV2 cells as previously described 57 . Briefly, about 30 million BV2 cells stably expressing EF1-alpha-Cas9-Blast were infected with the 10 guide/gene sgRNA sublibrary (see Supplementary  Table 2 for the gene list) at a multiplicity of infection of <1. Infected cells underwent puromycin selection (1.5 μg ml -1 ) for 7 days; after this time period, puromycin was removed and cells were resuspended in normal growth medium (DMEM + 10% FBS) without puromycin. After selection, sgRNA infection was confirmed by flow cytometry, which indicated that >90% of cells expressed the mCherry reporter. Cells were cultured at ×1,000 coverage (about 1,000 cells containing each sgRNA) throughout the screen. BV2 cells were treated for 18 h with 5 μg ml -1 LPS in DMEM with 5% FBS to induce lipid droplet formation, and the photoirradiation assay was performed as described above (see the section "iBP irradiation assay" above). Nonirradiated, LPS-treated BV2 cells were used as controls. After irradiation, cells were washed twice in medium and put back in the incubator. LPS treatment and photoirradiation were performed three times, with 24 h of recovery time between each irradiation and the next LPS treatment. At the end of the screen, genomic DNA was extracted for all experimental conditions using a Blood Midi kit (Qiagen). Deep sequencing of sgRNA sequences on an Illumina Nextseq was used to monitor library composition. Guide composition was analyzed and compared to the plasmid library between conditions using castle v.1.0 (ref. 5 ) available at https://bitbucket.org/dmorgens/castle. Genes with FDR values of <50% were considered as significant hits.
Generation of single CRISPR-Cas9 knockout BV2 cells.
Lentivirus production and infection were performed as previously described 57 . Briefly, HEK293T cells were transfected with packaging plasmids and sgRNA-containing plasmids. Supernatant was collected at 48 h and 72 h and concentrated using Lenti-X solution (Clontech). BV2 cells stably expressing Cas9 under blasticidin (1 μg ml -1 ) selection were infected with lentivirus containing sgRNA plasmids under puromycin selection for 24 h. Puromycin selection was started 48 h after infection and maintained for 7 days. Grn knockout BV2 cells were subcloned to maintain a monoclonal knockout population. Slc33a1 and Vps35 single-knockout cell lines were assayed as polyclonal populations.
Cytokine assay. Primary microglia from hippocampi of 3-month-old (young) and 20-month-old (aged) male wild-type mice and from 10-month-old male Grn −/− mice were isolated as described above ("Microglia isolation"; hippocampi from three mice were pooled per age group). CD11b + CD45 lo primary microglia from young mice, and CD11b + CD45 lo primary microglia sorted for BODIPY lo and BODIPY hi cells from aged mice, were sorted into 5% FBS-containing microglial culture medium (DMEM/F12, 1% pen/strep; 2 mM glutamine, 5 µg ml -1 Nacetyl cysteine, 5 µg ml -1 insulin, 100 µg ml -1 apo-transferrin, 100 ng ml -1 sodium selenite, 2 ng ml -1 human TGF2, 100 ng ml -1 murine IL-34, 1.5 µg ml -1 ovine wool cholesterol, 10 µg ml -1 heparin sulfate) 7 . Cells were seeded into 96-well plates at 5,000 cells per well in 100 μl microglia culture medium with 5% FBS and incubated for 30 min in the incubator (37 °C, 5% CO 2 ). Next, cells were treated with 100 ng ml -1 LPS or PBS for 8 h, supernatant was collected, and secreted signaling proteins were measured in culture supernatants using a Mouse Cytokine/ Chemokine Array 31-Plex (Eve Technologies). NAD/NADH assay. Primary microglia from 3-month-old (young) and 20-monthold (aged) wild-type mice were isolated as described above ("Microglia isolation"; hippocampi from three mice were pooled per group), and CD11b + CD45 lo primary microglia from young mice, and CD11b + CD45 lo primary microglia sorted for BODIPY lo and BODIPY hi cells from aged mice, were sorted into 5% FBScontaining microglial culture medium (see "Cytokine assay" above). Cells were seeded into 96-well white-walled tissue culture plates at 5,000 cells per well in 50 μl microglial culture medium with 5% FBS and incubated for 30 min in the incubator (37 °C, 5% CO 2 ). A NAD/NADH-Glo assay (Promega) was performed according to manufacturer's instructions. Cell lysates were incubated for 2 h at RT, and luminescence was recorded using a luminometer (Lmax, Molecular Devices).
Statistical analyses. Data collection was randomized for all experiments. Experimenters were blinded for imaging and data analyses. No sample size calculations were performed. Sample sizes were determined to be adequate based on the magnitude and consistency of measurable differences between groups. Furthermore, sample sizes were chosen based on prior literature using similar experimental paradigms. Statistical analyses were performed using the software GraphPad Prism 5.0 (GraphPad Software), and the R DESeq2 package was used for RNA-seq analysis. Data were tested for normality using the Kolmogorov-Smirnov or the Shapiro-Wilk test, and equality of variance was confirmed using the F-test. Means between two groups were compared using two-tailed unpaired Student's t-test or, in case of non-Gaussian distribution, using two-tailed Mann-Whitney U-test. Data from multiple groups were analyzed by one-way analysis of variance (ANOVA) and two-way ANOVA, followed by Tukey's post hoc tests. Detailed information on sample size, numbers of replicates and statistical test used for each experiment is provided in the figure legends. 
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
No sample-size calculations were performed. Sample size was determined to be adequate based on the magnitude and consistency of measurable differences between groups. Further, sample sizes were chosen based on prior literature using similar experimental paradigms.
Data exclusions For osmotic pump infusions, 3 mice were excluded and euthanized prior to experiment endpoint due to post-operative wound dehiscence. These exclusion criteria were predetermined as per relevant animal protocols.
Replication
For in vitro experiments, technical triplicates were performed. For in vivo experiments, biological replicates as well as independent cohorts of mice were used. CRISPR screen data and RNA-seq data were not replicated in independent experiments due to resource restrictions. All other data were replicated in at least two independent experiments as stated in figure legends. All attempts for replication were successful.
Randomization Data collection was randomized for all experiments.
Blinding
Experimenters were blinded for imaging and data analysis.
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Materials
Validation
All antibodies used were validated by manufacturers. Furthermore, antibodies were validated by adding 2nd Antibody controls (withdrawal of primary antibody), and by cellular localization and morphology of stained structures (CD68, Adipophilin, Perilipin3) and by the morphology of stained cells (Iba1,
